These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26081481)

  • 1. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
    Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
    J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
    Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life.
    Loochi SA; Demol S; Nagelberg N; Lebenthal Y; Phillip M; Yackobovitch-Gavan M
    J Pediatr Endocrinol Metab; 2021 Mar; 34(3):373-383. PubMed ID: 33609438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
    Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog.
    Ramos CO; Macedo DB; Canton APM; Cunha-Silva M; Antonini SRR; Stecchini MF; Seraphim CE; Rodrigues T; Mendonca BB; Latronico AC; Brito VN
    Neuroendocrinology; 2020; 110(7-8):705-713. PubMed ID: 31671431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.
    Alessandri SB; Pereira Fde A; Villela RA; Antonini SR; Elias PC; Martinelli CE; Castro Md; Moreira AC; Paula FJ
    Clinics (Sao Paulo); 2012; 67(6):591-6. PubMed ID: 22760897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.
    Lem AJ; van der Kaay DC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Jan; 98(1):77-86. PubMed ID: 23125290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
    Magiakou MA; Manousaki D; Papadaki M; Hadjidakis D; Levidou G; Vakaki M; Papaefstathiou A; Lalioti N; Kanaka-Gantenbein C; Piaditis G; Chrousos GP; Dacou-Voutetakis C
    J Clin Endocrinol Metab; 2010 Jan; 95(1):109-17. PubMed ID: 19897682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
    Lerman L; Yackobovitch-Gavan M; Phillip M; Shalitin S
    Pediatr Res; 2024 Mar; 95(4):1051-1059. PubMed ID: 37935883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final adult height in children with central precocious puberty - a retrospective study.
    Knific T; Lazarevič M; Žibert J; Obolnar N; Aleksovska N; Šuput Omladič J; Battelino T; Avbelj Stefanija M
    Front Endocrinol (Lausanne); 2022; 13():1008474. PubMed ID: 36531464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty.
    Thornton P; Silverman LA; Geffner ME; Neely EK; Gould E; Danoff TM
    Pediatr Endocrinol Rev; 2014 Mar; 11(3):306-17. PubMed ID: 24719967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.